Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Inclusion Criteria: * Must have given written informed consent (signed and dated) and any authorizations required by local law. * Willing to be confined to CRU for the entire duration required by the protocol. * Male or female, between 18 and 80 years of age. * Healthy subject with normal liver function must be non-smoker and no use of other tobacco or nicotine-containing products. Subject with HI must be non-smoker, or smoke ≤10 cigarettes per day during the study. * Healthy subject must not be taking any prescribed or non-prescribed medications unless permitted. Subject with HI will be allowed to take their chronic medications unless excluded by the protocol. Exclusion Criteria: * Pregnant or lactating women. * Treatment with another investigational drug or device within 30 days prior to study drug administration. * Has donated or lost a significant volume of blood within 56 days or plasma within 7 days prior to Check-in day. * Inability to swallow medication. * Positive test for drugs of abuse and/or positive alcohol test at Screening or Day -1. * Positive test at Screening for HBsAg, hepatitis C virus (HCV), or HIV.